Cand.scient. Aslaug Aamodt Muggerud from Anne-Lise Børresen-Dale's group at the Department of Genetics at the Institute for Cancer Research gave her trial lecture on the subject "Clinical utility of genetic and epigenetic markers in the management of cancer. Current status" on Friday November 13th at 10.30.
She defends her PhD thesis - entitled "Genetic and epigenetic alterations in breast tumour progression: The transition from in situ to invasive cancer" on Friday November 13th at 13.15.
Venue for both events: Auditorium U1, The Norwegian Radium Hospital at Montebello.
From major journals, first or last author from the Institute for Cancer Research
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Adv Drug Deliv Rev, 186, 114326 (in press)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Nucleic Acids Res (in press)